Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
Data
2020Autor
Boettler, Tobias
Marjot, Thomas
Newsome, Philip N.
Mondelli, Mario U.
Maticic, Mojca
Cordero, Elisa
Jalan, Rajiv
Moreau, Richard
Cornberg, Markus
Berg, Thomas
Metadata
Mostrar registro completo
Documentos PDF
Resumo
During the early stages of the COVID-19 pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. In the meantime, many countries and healthcare systems have been, or are still overwhelmed by the pandemic, significantly impacting on the care of this group of patients, whilst others have started to return towards their usual routine. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the course of the disease have to be kept in mind when caring for patients with COVID-19. Thus, this review should serve as an update on the previous position paper summarizing the evidence for liver disease involvement during COVID-19 and also provide some recommendations on how to return to routine care wherever possible.
Palabras clave
ACE-I; Angiotensin-converting enzyme inhibitor; ACE2; Acute-on-chronic liver failure; ALT; Metabolic-dysfunction associated fatty liver diseaseLink para o recurso
https://doi.org/10.1016/j.jhepr.2020.100169Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.